ensartinib (Ensacove)

Indications

• first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)

* doubles mean progression-free survival 26 months vs crizotinib 13 months, but does not increase overall survival

Dosage

• 225 mg PO QD with or without food*

* until disease progression or unacceptable toxicity

Adverse effects

• >= 20%
  • rash, pruritus, musculoskeletal pain, nausea, constipation, cough, edema, pyrexia, fatigue.

More general terms

• small inhibitory antineoplastic agent (ib drug)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=56960363
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=138320013